Clinical Trials Directory

Trials / Conditions / Stage IV Lung Non-Small Cell Cancer AJCC v7

Stage IV Lung Non-Small Cell Cancer AJCC v7

23 registered clinical trials studyying Stage IV Lung Non-Small Cell Cancer AJCC v7 — 1 currently recruiting.

StatusTrialSponsorPhase
TerminatedSitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC
NCT04925986
Sarah GoldbergPhase 2
CompletedNivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell L
NCT03468985
National Cancer Institute (NCI)Phase 2
RecruitingTesting Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149
National Cancer Institute (NCI)Phase 2
TerminatedPembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Ca
NCT03325166
OHSU Knight Cancer InstitutePhase 2
Active Not RecruitingDurvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metas
NCT02888743
National Cancer Institute (NCI)Phase 2
TerminatedImage Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizuma
NCT03050060
University of WashingtonPhase 2
Active Not RecruitingTesting the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) M
NCT02503722
National Cancer Institute (NCI)Phase 1
Active Not RecruitingA Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
NCT02498613
National Cancer Institute (NCI)Phase 2
CompletedOsimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic N
NCT02520778
National Cancer Institute (NCI)Phase 1
Active Not RecruitingThermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Co
NCT02713269
M.D. Anderson Cancer CenterPhase 2
Active Not RecruitingTrametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell
NCT02642042
National Cancer Institute (NCI)Phase 2
Active Not RecruitingCeritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-I
NCT02321501
M.D. Anderson Cancer CenterPhase 1
CompletedErlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant No
NCT02535338
National Cancer Institute (NCI)Phase 1 / Phase 2
TerminatedGenetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
NCT02706392
Fred Hutchinson Cancer CenterPhase 1
CompletedMethoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With St
NCT02535325
National Cancer Institute (NCI)Phase 1
Active Not RecruitingPembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Trea
NCT02444741
M.D. Anderson Cancer CenterPhase 1 / Phase 2
TerminatedNintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small
NCT02452463
Roswell Park Cancer InstitutePhase 2
Active Not RecruitingErlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in T
NCT01708954
National Cancer Institute (NCI)Phase 2
CompletedErlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Can
NCT01532089
Academic and Community Cancer Research UnitedPhase 2
CompletedAzacitidine in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
NCT01281124
National Cancer Institute (NCI)Phase 2
TerminatedCarboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung C
NCT01413750
National Cancer Institute (NCI)Phase 2
TerminatedRO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metas
NCT01217411
National Cancer Institute (NCI)Phase 1 / Phase 2
CompletedErlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-
NCT00126581
National Cancer Institute (NCI)Phase 2